High Prevalence of Abnormal Nocturnal Oximetry in Patients With Hypertrophic Cardiomyopathy  by Eleid, Mackram F. et al.
H
h
p
p
s
c
t
(
F
I
†
M
s
C
g
R
a
Journal of the American College of Cardiology Vol. 54, No. 19, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
PHigh Prevalence of Abnormal Nocturnal
Oximetry in Patients With Hypertrophic Cardiomyopathy
Mackram F. Eleid, MD,* Tomas Konecny, MD,† Marek Orban, MD,† Partho P. Sengupta, MD, DM,*
Virend K. Somers, MD, PHD,† James M. Parish, MD,* Farouk Mookadam, MBBS,*
Peter A. Brady, MD,† Barbara L. Sullivan, NP,* Bijoy K. Khandheria, MD,* Steve R. Ommen, MD,†
A. Jamil Tajik, MD*
Scottsdale, Arizona; and Rochester, Minnesota
Objectives We sought to determine the prevalence of nocturnal oxygen desaturation and obstructive sleep apnea (OSA) in a
population of patients with hypertrophic cardiomyopathy (HCM).
Background The coexistence of sleep apnea and HCM, 2 common cardiovascular conditions, has been largely unrecognized
in the treatment of patients with HCM. The nocturnal hypoxia-induced hyperadrenergic state in OSA is expected
to worsen hemodynamics and outcomes in HCM.
Methods One hundred subjects with HCM between June 1, 2006, and July 14, 2008, were screened with nocturnal oxime-
try. Clinical variables were collected for statistical analysis. Oximetry was classified abnormal (suspicion of sleep-
disordered breathing) in the presence of repetitive desaturation (5 events/h) followed by a rapid return to
baseline oxygen saturation (SaO2) level with a decrease of 4% and threshold of 90%.
Results Seventy-one (71%) patients with HCM had abnormal nocturnal oximetry (71  9%, 95% confidence interval:
62% to 80%). Subjects with abnormal oximetry were older (age 59.5  15.3 years) and more were hypertensive
(n  39 [55%]) than those with normal oximetry (age 45.8  18.5 years, n  9 [31%], p  0.001, p  0.03).
Patients with HCM were more symptomatic in the presence of abnormal oximetry (New York Heart Association
functional class II to III) (62% vs. 83%, p  0.023). HCM patients had a higher prevalence of abnormal nocturnal
oximetry (n  71, 71%) compared with a control group of similar age and sex distribution (n  49, 49%) (p 
0.001).
Conclusions Abnormal nocturnal oximetry is common in patients with HCM, suggesting that OSA is prevalent. OSA may im-
pact hemodynamics and symptoms in HCM. Further studies are needed to determine the long-term benefit of
OSA treatment on hemodynamics and disease progression in HCM. (J Am Coll Cardiol 2009;54:1805–9)
© 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.030d
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iypertrophic cardiomyopathy (HCM) is the most common
eritable cardiovascular disease with a prevalence that ap-
roaches 1 in 500 (1). One in 5 individuals in the general
opulation (9% to 12% of women and 27% to 35% of men)
uffer from obstructive sleep apnea (OSA), an acquired
linical condition that is currently recognized as an impor-
ant reversible cause of left ventricular (LV) hypertrophy
2,3). Furthermore, both HCM and OSA are indepen-
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esearch.H
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ccepted July 30, 2009.ently associated with an increased risk of sudden cardiac
eath (1,2). Whether the 2 diseases commonly coexist in
atients has not been examined.
See page 1810
Current guidelines acknowledge a fundamental treatment
oal of HCM is alleviation of symptoms (1). Symptoms
uch as dyspnea, angina, and syncope can be difficult to
ontrol with pharmacologic therapy and are associated with
igher mortality in HCM patients (4–6). Nonpharmaco-
ogic measures including surgical myectomy and alcohol
eptal ablation are often necessary for drug refractory symp-
omatic patients with LV outflow tract obstruction. Until
ecently, no studies have investigated if OSA may be an
mportant contributor to drug refractory symptoms inCM.
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Abnormal Oximetry and HCM November 3, 2009:1805–9Dynamic LV outflow tract ob-
struction, a hallmark of HCM, is
aggravated and potentiated by
sympathetic stimulation. The
nocturnal hypoxia-induced hy-
peradrenergic state known to ex-
ist in OSA is expected to worsen
the hemodynamics in HCM (7).
This study was prompted by our
recent observation that patients
with symptomatic HCM and
OSA show improvement in
symptoms after successful treat-
ment of OSA. We have recently
reported cases of HCM patients
who experienced reduction of
ymptoms and outflow tract obstruction after treatment of
SA with continuous positive airway pressure (CPAP) (8).
creening with nocturnal oximetry of the HCM population
ould be useful if sleep-disordered breathing is found to be
n important comorbidity. We sought to determine the
revalence of abnormal nocturnal oximetry in the HCM
opulation.
ethods
atients with HCM diagnosed by echocardiography be-
ween June 1, 2006, and July 14, 2008 were screened for
ndiagnosed sleep-disordered breathing with nocturnal
ximetry. The majority of patients were enrolled from
ertiary referral specialty clinics at Mayo Clinic in Arizona
nd Minnesota dedicated to the management of HCM.
creening with oximetry was performed as a routine, re-
ardless of suspicion for underlying sleep-disordered
reathing. Demographic, laboratory, echocardiographic,
ximetry, and other clinical variables were collected into an
lectronic database for statistical analysis. New York Heart
ssociation (NYHA) functional class was obtained through
eview of clinical information. A subset of HCM patients
lso had formal polysomnography, which was completed for
linically indicated purposes per the treating physician.
A control group of patients with similar age and sex
ithout HCM was used for comparison with HCM pa-
ients. All individuals in the control group had no prior
iagnosis of sleep-disordered breathing or significant pul-
onary disease and were screened with nocturnal oximetry
y their treating physicians for underlying sleep apnea at our
nstitution between January 1, 2007, and February 28, 2007.
CM. The diagnosis of HCM was based on the echocar-
iographic criteria of LV hypertrophy with LV wall thick-
ess 15 mm in a nondilated, hyperdynamic LV in which
he degree of hypertrophy is not explained by another
ardiac or systemic disease, such as longstanding hyperten-
ion (1).
ximetry. Patients were provided with a pulse oximeter
Abbreviations
and Acronyms
BMI  body mass index
CPAP  continuous
positive airway pressure
HCM  hypertrophic
cardiomyopathy
LV  left ventricle/
ventricular
NYHA  New York Heart
Association
OSA  obstructive sleep
apnea
SaO2  oxygen saturationNonin 2500 PalmSAT [Nonin, Plymouth, Minnesota], campling rate 4 s) and instructed in its use. Oximetry data
ere downloaded and displayed with Profox software (Pro-
ox, Escondido, California). Nocturnal oximetry was inter-
reted by board-certified pulmonologists and classified as
bnormal (suspicion of sleep-disordered breathing) if the
umber of desaturation episodes was greater than 5 events/h
f recording time followed by a rapid return to the baseline
xygen saturation (SaO2) level. A desaturation event was
efined as a decrease in SaO2 level of at least 4%, with a
hreshold of 90% (9).
tatistical analysis. Clinical data were reported as mean 
D or n (%). For proportion of subjects with abnormal
ximetry, a 95% confidence interval was calculated. For
ndependent groups (both control vs. HCM and abnormal
s. normal oximetry groups) the chi-square test was used to
ompare categorical variables, while the Student t test was
sed for continuous variables. A box plot diagram was used
o depict the relationship of nocturnal hypoxia with NYHA
unctional class.
esults
f 100 patients with HCM, 71 (71%) had abnormal
octurnal oximetry (presence of episodes of transient de-
aturation followed by a rapid return to the baseline SaO2
evel) (95% confidence interval: 71  9%, range 62% to
0%). The abnormal oximetry group (group A) contained
2 (59%) men, average age 59.5  15.3 years, body mass
ndex (BMI) 31.1  6.5 kg/m2, 39 (55%) with hyperten-
ion, 38 (53%) with hyperlipidemia, 5 (7%) with diabetes
ellitus, 59 (83%) with NYHA functional class II to III,
nd 52 (73%) with obstructive variant and mean resting LV
utflow tract peak gradient 42.6  29.9 mm Hg (Table 1).
total of 24 subjects from group A also had formal
olysomnography, which confirmed the diagnosis of OSA
n 23 (96%). Control group characteristics compared with
CM patients are summarized in Table 2. Risk factors for
SA including age, sex, hypertension, BMI, and smoking
istory were not significantly different between the 2 groups.
he HCM group had a higher prevalence of abnormal
octurnal oximetry (n  71, 71%) compared with the
ontrol group (n  49, 49%) (p  0.001).
Of 29 subjects (29%) with normal nocturnal oximetry
group B), 13 (45%) were men, average age 45.8  18.5
ears, BMI 28.9 7.3 kg/m2, 9 (31%) had hypertension, 12
41%) had hyperlipidemia, 1 (3%) had diabetes mellitus, 18
62%) had NYHA functional class II to III, and 18 (62%)
ad obstructive variant and mean resting LV outflow tract
eak gradient 35.3  35.2 mm Hg.
HCM subjects with abnormal oximetry were older and
ore likely to be hypertensive than those with normal
ximetry (p  0.001 and p  0.03, respectively). A
ignificantly higher number of subjects with abnormal oxime-
ry also had an abnormal NYHA functional class (II to III)
p  0.023) (Table 1). Resting LV outflow tract gradient also
orrelated with degree of symptoms (p  0.005) (Fig. 1).
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November 3, 2009:1805–9 Abnormal Oximetry and HCMocturnal oximetry recordings. The average number of
esaturation events for HCM patients with abnormal oxim-
try (n  71) was 11.6  12.5 events/h. The average mean
aO2 was 93  2.0% and the average minimum SaO2 was
2.3  6.2%. Among subjects with abnormal oximetry,
hose with NYHA functional class III symptoms had a
igher duration of nocturnal hypoxia (16.7 23.7% of time
pent at SaO2 90%) than those with no symptoms (3.2 
.0% of time spent at SaO2 90%) (p  0.006) (Fig. 2).
iscussion
ell-established risk factors for OSA include increasing
ge, obesity, male sex, and cigarette smoking (10,11). In
CM Subjects (n  100)Table 1 HCM Subjects (n  100)
Characteristics
Abnormal
Oximetry
(n  71, 71%)*
Normal
Oximetry
(n  29, 29%) p Value
Age 59.5 15.3 45.8 18.5 0.001
BMI (kg/m2) 31.1 6.5 28.9 7.3 0.159
Men 42 (59%) 13 (45%) 0.191
Hypertension 39 (55%) 9 (31%) 0.030
Diabetes mellitus 5 (7%) 1 (3%) 0.823
Active smoking 6 (8%) 5 (17%) 0.356
Former smoking 23 (32%) 7 (24%) 0.4779
NYHA functional class II to III 59 (83%) 18 (62%) 0.023
IVS (mm) 19.0 5.9 20.7 6.0 0.184
EF (%) 68 7.6 69 5.8 0.518
Obstructive HCM 52 (73%) 18 (62%) 0.269
LVOT resting peak gradient
(obstructive patients; n  70)
42.6 29.9 35.3 35.2 0.433
Left atrial volume index (cc/m2) 46.7 19.4 42.5 12.0 0.239
E/A ratio 1.19 0.67 1.35 0.75 0.199
Right ventricular systolic
pressure (mm Hg)
34.0 8.3 33.7 12.0 0.510
24 subjects also had a formal polysomnogram, which confirmed the diagnosis of obstructive
leep apnea in 23 (96%).
BMI  body mass index; EF  ejection fraction; HCM  hypertrophic cardiomyopathy; IVS 
nterventricular septal thickness; LVOT  left ventricular outflow tract; NYHA  New York Heart
ssociation.
CM and Control PatientsTable 2 HCM and Control Patients
HCM Group
(n  100)
Control Group
(n  100) p Value
Age 55.5 17.4 56.3 7.7 0.68
BMI (kg/m2) 30.4 6.8 30.2 5.5 0.77
Men 55 (55%) 55 (55%) 1.00
Hypertension 48 (48%) 39 (39%) 0.20
Diabetes mellitus 6 (6%) 5 (5%) 0.76
Active smoking 11 (11%) 14 (14%) 0.52
Former smoking 30 (30%) 39 (39%) 0.18
Abnormal oximetry 71 (71%) 49 (49%) 0.001
IVS (mm) 19.5 6.0 11.2 2.2 0.001
EF (%) 69 7.1 61 8.3 0.001
Left atrial volume index (cc/m2) 35 11 28 7.4 0.001
E/A ratio 1.25 0.67 1.24 0.52 0.85
Right ventricular systolic
pressure (mm Hg)
35 11 29 8.7 0.003bbreviations as in Table 1.act, it is estimated that over 25% of the U.S. population is
t risk for OSA (10). While it seems highly probable that
ome patients with HCM should also have OSA, there has
een little research into this area. In our study, we found a
igh prevalence of abnormal oximetry in the HCM popu-
ation, particularly in patients that were middle to older age,
ypertensive, and symptomatic. Furthermore, patients with
YHA functional class III symptoms had more nocturnal
ypoxia (longer percentage of time 90% SaO2) than those
ithout symptoms, suggesting an association between
ymptoms and severity of sleep-disordered breathing in
CM patients.
The high prevalence of hypertension in the abnormal
ximetry group (55%) compared with the normal oximetry
roup (31%) is not surprising, given the independent asso-
Figure 1 Resting Peak Gradient and NYHA Functional Class
Resting peak left ventricular outflow tract (LVOT) gradient in subjects with
hypertrophic cardiomyopathy and relationship with symptom severity by New
York Heart Association (NYHA) functional class (p  0.005).
Figure 2 Nocturnal Hypoxia and NYHA Functional Class
Duration of nocturnal hypoxemia in subjects with hypertrophic cardiomyopathy
and relationship with symptom severity by New York Heart Association (NYHA)
functional class (p  0.006). SaO  oxygen saturation.2
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Abnormal Oximetry and HCM November 3, 2009:1805–9iation between sleep-disordered breathing and hyperten-
ion (12). OSA results in sympathetic nervous system
ctivation as well as nocturnal endothelin release, both of
hich contribute to elevated blood pressure throughout the
ay (7). Similar to individuals in our study with abnormal
ximetry (both with and without HCM), the prevalence of
ypertension in the general U.S. population age 60 or older
s estimated to be 50% and 75% in non-Hispanic white men
nd women, respectively (13).
iagnosis of OSA. OSA is caused by collapse of the
haryngeal airway during sleep, which results in recurrent
nterruption of ventilation (14). Collapse of the airway can
esult in either apnea (10 s cessation of respiration with
ngoing ventilatory effort) or hypopnea (a decrease [but not
essation] in respiratory effort with associated arousal or fall
n oxygen saturation). The apnea hypopnea index, defined
s the number of apneas and hypopneas during 1 h of sleep,
s derived from formal polysomnography. An apnea hypo-
nea index 5 coupled with symptoms of excessive daytime
leepiness are considered diagnostic for OSA (14).
ossible physiologic interaction. Patients with OSA have
levated catecholamine levels, which have been shown to
ormalize after CPAP treatment (15). Elevated catechol-
mine states can worsen the obstruction and diastolic
ysfunction in HCM, thus decreasing cardiac output, in-
reasing LV filling pressures, and worsening dyspnea and
izziness (16). Furthermore, sympathetic activation from
SA is associated with subendocardial ischemia, which
evelops from impairment of the coronary microvascular
ow due to shortened diastole, impaired diastolic function,
nd impaired coronary vasodilator capacity (17). Leptin, a
eptide hormone known to cause cardiac myocyte hyper-
rophy, has elevated serum concentration in patients with
SA and may further contribute to disease and symptom
rogression (18,19).
linical implications. Occult OSA, an increasingly com-
on condition in the developed world, may account for
ome of the symptom complex experienced by patients with
CM. Contrary to initial belief, symptoms of HCM have
ot been shown to correlate well with the degree of resting
eak LV outflow tract gradient (20). Recently, we reported
he first case series of HCM patients who experienced
eduction in resting LV outflow tract gradient as well as
ymptom reduction after treatment of OSA (8). Many
CM patients who have drug refractory symptoms ulti-
ately require invasive septal reduction procedures, which
arry their own risk. It is postulated that timely therapy with
PAP in patients with OSA may reduce the need for
urgical myectomy or alcohol septal ablation.
Given the potential adverse effects of nocturnal
ypoxemia-induced sympathetic activation on HCM symp-
oms and outcomes coupled with the high prevalence of
bnormal oximetry in this population, we recommend
creening and appropriate management for OSA in patients
ith HCM. Subjects with abnormal oximetry in our study
ere significantly older and more likely to have symptoms ofyspnea, angina, syncope, or palpitations. Such HCM
atient characteristics may be associated with an increased
isk of sleep-disordered breathing. Treatment of OSA with
PAP is known to reduce blood pressure, sympathetic
ctivity, and systemic inflammation (21). Potential benefits
rom identifying and treating this condition in HCM
nclude symptom reduction, improved cardiac function, and
ecreased need for invasive septal reduction therapy. As
reviously described, some HCM patients with OSA have
een observed to have resolution of resting LVOT obstruc-
ion after successful CPAP treatment.
tudy limitations. The findings in our study represent an
bservational cohort and require prospective confirmation.
hile nocturnal oximetry is a beneficial screening test for
SA, it does not establish a diagnosis and requires confir-
atory polysomnography. A subset of our patients did
roceed on to polysomnography, which established the
iagnosis of OSA. Our relatively small patient population
ay not reflect that of the general HCM population as they
resented to a tertiary referral center for their care, and
any were symptomatic.
onclusions
bnormal nocturnal oximetry is a common finding in the
CM population, suggesting that OSA is also highly
revalent in these patients. OSA with associated sympa-
hetic activation has the strong potential to negatively
mpact HCM hemodynamics and outcomes. Based on these
ata, we recommend screening and appropriate manage-
ent for OSA in the HCM population. Occult OSA may
ccount for some of the cases of drug refractory symptoms
xperienced by patients with HCM. Further studies are
eeded to determine the true prevalence of OSA in HCM
nd the effect of treatment of OSA on symptoms, hemo-
ynamics, and disease progression in HCM.
eprint requests and correspondence: Dr. A. Jamil Tajik,
ardiovascular Diseases, Mayo Clinic Arizona, 13400 East Shea
oulevard, Scottsdale, Arizona 85259. E-mail: jtajik@mayo.edu.
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